Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Slides:

Advertisements

Similar presentations

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Advertisements

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

Date of download: 6/26/2016 From: Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter- Defibrillator Versus.

Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I

Intramyocardial bone marrow mononuclear cell transplantation in ischemic heart failure: Long-term follow-up Miia Lehtinen, MD, Tommi Pätilä, MD, PhD,

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Mariell.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy? Wayne C. Levy,

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management E.A. Hamad, V. Devlin, K. McDonnell, N. Robinson, M. Welsh, E. Kerr,

Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score

Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation - Comparison of Systematic Mitral Valve Repair vs Surgical Abstention

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients James K. Kirklin, MD, David C. Naftel,

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation Ratika Parkash, MD, MSc, François Philippon,

Myocarditis in Clinical Practice

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Diabetes Mellitus and Heart Failure

Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection Derek V. Exner, MD, MPH, David.

Clyde W. Yancy et al. JACC 2017;70:

Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)

The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice Jonathan G. Howlett, MD, FRCPC, Michael Chan, MBBS,

Volume 5, Issue 4, Pages (April 2008)

Long-Term Follow-Up of Cardiac Rhythm in 320 Patients After the Cox-Maze III Procedure for Atrial Fibrillation Anders Albåge, MD, PhD, Birgitta Johansson,

The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy John W.C.

Volume 6, Issue 10, Pages (October 2009)

Volume 9, Issue 8, Pages S3-S13 (August 2012)

Volume 11, Issue 1, Pages (January 2014)

David D. Berg et al. JACC 2018;71:

Misconceptions and Facts About Hypertrophic Cardiomyopathy

Volume 6, Issue 12, Pages (December 2009)

Volume 13, Issue 7, Pages (July 2016)

Volume 7, Issue 1, Pages (January 2010)

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices Ranjit John, MD, Kenneth Liao,

Durable Mechanical Circulatory Support in Advanced Heart Failure

Elucidating the intricate mechanisms of gastrointestinal bleeding in a continuous-flow left ventricular assist device will lead to future therapeutic.

Advancing the science of myocardial recovery with mechanical circulatory support: A Working Group of the National, Heart, Lung, and Blood Institute Stavros.

Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication? Nishant D. Patel, BA, Jason.

Robotic-enhanced biventricular resynchronization: an alternative to endovenous cardiac resynchronization therapy in chronic heart failure Jean-Luc Jansens,

Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation? James K. Kirklin, MD, David C. Naftel,

Initial Clinical Experience With the Symphony Heart Assist System

Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C

Ethnic and racial disparities in cardiac resynchronization therapy

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

Discussions in Cardiothoracic Treatment and Care: Mechanical Circulatory Support Left Ventricular Assist Device Therapy for Patients With Advanced Heart.

Repeated molecular genetic analysis in Brugada syndrome revealed a novel disease- associated large deletion in the SCN5A gene Anders Krogh Broendberg,

Volume 7, Issue 7, Pages (July 2010)

Volume 12, Issue 10, Pages (October 2015)

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9- Year Experience Jeffrey A. Morgan, MD, Pauline H. Go, MD, Linnea.

Abdul Rahman Dakkak, MD, Angelo M. Dell'Aquila, MD, Juergen R

Volume 9, Issue 8, Pages S14-S17 (August 2012)

Right ventricular failure after cardiac surgery: Why can't right ventricular assist device support fix the problem? Francis D. Pagani, MD, PhD The Journal.

Volume 15, Issue 1, Pages (January 2018)

Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011 William L.

Appropriate use of genetics in a young patient with atrioventricular block and family history of sudden cardiac death Johnni Rudbeck-Resdal, MD, Jens.

Chronic obstructive pulmonary disease severity influences outcomes after off-pump coronary artery bypass Benjamin Medalion, MD, Michael G. Katz, MD,

James O. O’Neill, MB, Randall C

Early Outcomes With Marginal Donor Hearts Compared With Left Ventricular Assist Device Support in Patients With Advanced Heart Failure Erin M. Schumer,

Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices Forum Kamdar, MD, Ranjit John,

James W. Long, MD, PhD, Aaron H. Healy, BS, Brad Y

Optimal timing for heart transplantation in patients bridged with left ventricular assist devices: Is timing of the essence? Chase R. Brown, MD, Fabliha.

Cardiac Resynchronization Therapy: Long-Term Alternative to Cardiac Transplantation? Bert Hansky, MD, Jürgen Vogt, MD, Armin Zittermann, PhD, Holger Güldner,

Daisuke Yoshioka, MD, Hiroo Takayama, MD, Arthur R. Garan, MD, Veli K

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Volume 16, Issue 6, Pages (June 2019)

Presentation transcript:

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator: A pilot study Stanislava Zabarovskaja, MD, Fredrik Gadler, MD, PhD, Anders Gabrielsen, MD, PhD, Cecilia Linde, MD, PhD, Lars H. Lund, MD, PhD The Journal of Heart and Lung Transplantation Volume 32, Issue 6, Pages 651-654 (June 2013) DOI: 10.1016/j.healun.2013.02.008 Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 1 Flow chart shows cardiac resynchronization therapy (CRT) or implantable cardioverter-defibrillator (ICD) patients screened for heart transplantation (HTx) and left ventricular assist device (LVAD). BTT, bridge-to-transplant; COPD, chronic obstructive pulmonary disease; DT, destination therapy; HF, heart failure; NYHA, New York Heart Association. *These 30 patients had ICD for other indications. #Patients with contraindication. Listed contraindications are not mutually exclusive. The Journal of Heart and Lung Transplantation 2013 32, 651-654DOI: (10.1016/j.healun.2013.02.008) Copyright © 2013 International Society for Heart and Lung Transplantation Terms and Conditions